BNTX241018P130000
- 19.90
- +4.50+29.22%
BioNTech Newsroom
He Made Pfizer a Household Name. Wall Street Wants More
BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed
European Equities Traded in the US as American Depositary Receipts Rise Friday
BioNTech Partial Clinical Hold an 'Incremental Negative,' Says Morgan Stanley
BioNTech Shares Slip as FDA Places Partial Clinical Hold on Lung Cancer Study
BioNTech's Cancer Trial Faces FDA Hold Challenges
BioNTech SE : FDA Has Placed Partial Clinical Hold on Two-stage, Open-label, Randomized Phase 3 Trial, PRESERVE-003
Novavax Stock Plummets 17% as FDA Pauses Clinical Trial on Safety Concerns -- Barrons.com
Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 3.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 15, $BioNTech(BNTX.US)$ 10% Stockholder ATHOS KG intends to sell 25,424 shares of its common stock on Oct 14, with a total market value of approximately $3.07 million.
Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 4.81 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Oct 11, $BioNTech(BNTX.US)$ 10% Stockholder ATHOS KG intends to sell 40,000 shares of its common stock on Oct 11, with a total market value of approximately $4.81 million.
Pfizer, BioNTech's Updated Covid-19 Vaccine Approved in UK for Adults
Express News | UK's Mhra: Approved an Adapted Pfizer/BioNTech Covid-19 Vaccine (Comirnaty) That Targets the Kp.2 Covid-19 Subvariant for Adults
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
UK Considers GBP129 Million Subsidy for BioNTech to Secure Investment
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Express News | Pfizer, BioNTech Win Bid in UK Court to Invalidate CureVac's Patents Over Mrna Technology in Covid-19 Vaccines
HSBC Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $136
BioNTech Is Maintained at Buy by HSBC
Morgan Stanley Upgrades BioNTech(BNTX.US) to Buy Rating, Raises Target Price to $145
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday